Patients want to know, “When should I get an mpox vaccine booster?” But the research to answer their question isn’t available ...

Stanford Medicine investigators have unearthed the biological process by which mRNA-based vaccines for COVID-19 can cause ...

Study points to source of "very, very rare" cases of myocarditis and potential solutions. Myocarditis risk remains far higher ...

A rapid, two-step immune reaction may underlie rare cases of heart inflammation seen after Covid mRNA vaccination, Stanford ...

The U.S. health regulator is investigating deaths potentially related to COVID-19 vaccines across multiple age groups as part ...

Dr. Vinay Prasad, the director of the FDA's vaccine division, did not provide data to back the claim in a memo sent to staff.

Moderna, an mRNA specialist known for its COVID-19 vaccine Spikevax, is winding down development of three clinical mRNA programs, including two investigational vaccines for infectious diseases. The ...

Moderna shares rose after the company posted a narrower third-quarter loss than Wall Street expected, a sign that its cost-cutting measures are helping offset the decline of its COVID business. The ...

Moderna MRNA-7.01%decrease; red down pointing triangle swung to a loss and logged lower sales in the third quarter as it works to expand its offerings amid weakening demand for its Covid-19 vaccine.

Moderna surged on reports of talks with a large biopharma for a potential partnership or buyout, despite trading at multi-year lows. MRNA's promising cancer vaccine data and surprising findings on ...

CAMBRIDGE, MA / ACCESS Newswire / October 22, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the Company’s ...